Effect of mitochondrial haplogroups on ranibizumab response in neovascular age-related macular degeneration patients: a pilot study
Esteban, O. ; Ascaso, F.J. (Universidad de Zaragoza) ; Mateo, J. ; Calvo, T. ; Montoya, J. (Universidad de Zaragoza) ; Ruiz-Pesini, E. (Universidad de Zaragoza)
Resumen: Editor,
Vascular endothelial growth factor (VEGF) is necessary for the formation of new blood vessels in neovascular age-related macular degeneration (nAMD). Thus, VEGF is a target for antiangiogenic intravitreal therapy in nAMD. One of these anti-VEGF agents is ranibizumab. Besides clinical factors, certain gene variants, that have been associated with nAMD prevalence, also influence the individual’s response to ranibizumab therapy (Dedania et al. 2015). Thus, a significant association between AMD risk and mitochondrial DNA (mtDNA) genetic background (haplogroup) has been repeatedly reported (Udar et al. 2009). We hypothesized that mtDNA genotype could partially explain the individual differences in response to ranibizumab. Patients included in the study were diagnosed of nAMD and received 3 initial monthly injections of intravitreal ranibizumab (IVR) 0.5 mg in 0.05 ml followed by a flexible pro re nata period for the remaining 8 months. The decision to re-treat was based on vision loss =5 letters...
Idioma: Inglés
DOI: 10.1111/aos.13865
Año: 2018
Publicado en: ACTA OPHTHALMOLOGICA 97, 1 (2018), e133 - e134
ISSN: 1755-375X
Factor impacto JCR: 3.153 (2018)
Categ. JCR: OPHTHALMOLOGY rank: 12 / 59 = 0.203 (2018) - Q1 - T1
Factor impacto SCIMAGO: 1.51 - Ophthalmology (Q1) - Medicine (miscellaneous) (Q1)
Tipo y forma: (Published version)
Área (Departamento): Área Oftalmología (Dpto. Cirugía,Ginecol.Obstetr.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
Exportado de SIDERAL (2024-01-26-18:10:49)
Visitas y descargas
Vascular endothelial growth factor (VEGF) is necessary for the formation of new blood vessels in neovascular age-related macular degeneration (nAMD). Thus, VEGF is a target for antiangiogenic intravitreal therapy in nAMD. One of these anti-VEGF agents is ranibizumab. Besides clinical factors, certain gene variants, that have been associated with nAMD prevalence, also influence the individual’s response to ranibizumab therapy (Dedania et al. 2015). Thus, a significant association between AMD risk and mitochondrial DNA (mtDNA) genetic background (haplogroup) has been repeatedly reported (Udar et al. 2009). We hypothesized that mtDNA genotype could partially explain the individual differences in response to ranibizumab. Patients included in the study were diagnosed of nAMD and received 3 initial monthly injections of intravitreal ranibizumab (IVR) 0.5 mg in 0.05 ml followed by a flexible pro re nata period for the remaining 8 months. The decision to re-treat was based on vision loss =5 letters...
Idioma: Inglés
DOI: 10.1111/aos.13865
Año: 2018
Publicado en: ACTA OPHTHALMOLOGICA 97, 1 (2018), e133 - e134
ISSN: 1755-375X
Factor impacto JCR: 3.153 (2018)
Categ. JCR: OPHTHALMOLOGY rank: 12 / 59 = 0.203 (2018) - Q1 - T1
Factor impacto SCIMAGO: 1.51 - Ophthalmology (Q1) - Medicine (miscellaneous) (Q1)
Tipo y forma: (Published version)
Área (Departamento): Área Oftalmología (Dpto. Cirugía,Ginecol.Obstetr.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
Exportado de SIDERAL (2024-01-26-18:10:49)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
articulos
Notice créée le 2024-01-26, modifiée le 2024-01-26